Dr Isabella Premoli
Isabella graduated in Pharmacy from the University of Pavia (Italy) and pursued a Ph.D. in Behavioural Neuroscience at the University Hospital of Tübingen (Germany) in collaboration with the International Max Planck Research School. Her PhD focused on the investigation of GABAergic (inhibitory) neurotransmission by combining TMS and EEG under the administration of drugs with well-known and specific modes of action. In 2014, after joining the Richardson Lab at King’s College London, she established a new TMS-EEG facility within the Clinical Research Facility (CRF) of King’s College Hospital. Her work showed that TMS-EEG can measure GABA-mediated inhibitory processes and the pharmacological effects of several anti-epileptic drugs.
Isabella’s main work focused on the development of a novel technique named TMS-EEG which enables the assessment of human brain excitability in health and neurological conditions. Her interests span the application of TMS-EEG to investigate (i) human markers for pharmacological activity of drugs acting in the human brain; (ii) candidate markers of treatment outcome in schizophrenia patients; (iii) human markers for specific biological processes which are relevant to the pathophysiology of several brain disorders (i.e. epilepsy, ALS, Alzheimer’s and Parkinson’s diseases).